Institutional Biosafety Committee
Institutional Biosafety Committee (IBC)
The purpose of the 两性色午夜 University (KSU) Institutional Biosafety Committee (IBC) is to provide structured programming for teaching and/or research activities that involve recombinant or synthetic nucleic acid molecules and biohazardous materials, agents, and toxins, conducted under the auspices of KSU or are sponsored by KSU. Institutions that receive support from the National Institutes of Health (NIH) for recombinant or synthetic nucleic research are required to establish and register an IBC with the NIH Office of Biotechnology Activities (OBA) in compliance with the NIH Guidelines for Research Involving Recombinant DNA Molecules (NIH Guidelines).
The IBC is responsible for the oversight, administration, and review of KSU laboratory policies, practices, and projects involving teaching and research with recombinant or synthetic nucleic acid molecules and other potentially hazardous materials that may pose health, safety, or environmental risks. The IBC assists and advises the KSU Environmental Health and Safety Office, principal investigators (PIs), Institutional Animal Care and Use Committee, Institutional Review Boards, and other researchers to ensure that the aspects of teaching and/or research that fall within the purview of the IBC are conducted using established biosafety standards, principles, and work authorizations. Such advice includes worker safety, public health, prevention of human exposure to biological hazards, and environmental protection, ethics, and compliance with applicable biosafety standards and KSU Policies. The IBC is hereby-delegated authority to oversee teaching and/or research and approve laboratory protocols involving, but not limited to:
- Human cells, tissues, organs, blood, and bodily fluids.
- Any use of recombinant or synthetic nucleic acid encoding products dangerous to humans.
- Biological agents (animal, plant, bacterial, viral, prion, and/or their products) designated as risk group 1 in which genetic alteration with external genomic or synthetic nucleic acids extend or enhance their normal biological function.
- Biological agents (animal, plant, bacterial, viral, prion, and/or their products) designated as risk group 2.
- Transfected and/or transformed cell lines that pose human risk.
The IBC will investigate any concern, including those related to accidents, injuries or illness that may have resulted from the use of recombinant or synthetic nucleic acid molecules and biohazardous materials, agents, and toxins. If any valid concern or deviation from the NIH Guidelines or established policy, procedure, sound practice or protocol is found, the findings will be reported to the Principal Investigator, VPR, and relevant supporting units. Issues will be reported to the NIH according to NIH Policy.
-
Institutional Committee Members
Adam Jajtner PhD Chair Chris Woolverton PhD Vice Chair Westley Weiss Biosafety Officer Stanley Dannemiller DVM Animal Expert Sarah Eichler PhD Plant Expert Donald Gerbig PhD Biological Science Expert John Johnson PhD Biological Science Expert Kevin McCreary Director Research Sponsored Programs Aleisha Moore PhD Biological Sciences Expert Rocco Petrozzi DPM Physician Richard Piet PhD Biological Science Expert James Redfearn PhD Lab Representative Timothy Styranec Lab Representative LaKetta Wilson Voting Contact -
Institutional Committee Meeting Dates
Location: Virtual
Time: 2pm
All protocols must be received by the 1st Tuesday of the month to be reviewed at the monthly meeting.All meetings are subjected to change or cancellation. Contact the Environmental Health and Safety Office at 330-672-4347 or email compliance@kent.edu for questions or comments.
- July 23, 2024
- August 27, 2024
- September 24, 2024
- October 22, 2024
- November 19, 2024
- January 28, 2025
- February 25, 2025
- March 25, 2025
- April 22, 2025
- May 27, 2025
- June 24, 2025
-
Resources & Guidelines
DocumentDocumentDocument
-
Access Kuali IBC Application